Tianda Pharmaceuticals Limited announced that according to the Subscription Agreement, Tianda would provide certain undertakings to the Subscriber to procure the Directors to convene a board meeting and the Directors who are nominated by Tianda and its subsidiaries to attend such board meeting and vote in favour of the resolution for the appointment of a nominee to be nominated by the Subscriber as a non-executive Director and a member of the audit committee of the company. As part of it, the Board announce that Mr. SHEN has been appointed as a non-executive Director and a member of the audit committee of the Board with effect from 10 August 2015. Mr. SHEN has entered into a letter of appointment with the company for the appointment of Mr. SHEN as non-executive Director for a term of 2 years and his directorship is subject to the conditions as stated at the letter of appointment and retirement by rotation and re-election at the annual general meetings of the company pursuant to the articles of association of the company.

Since May 2014, Mr. SHEN concurrently acts as the executive director of China International Pharmaceutical (Holding) Corporation Limited (a wholly-owned subsidiary of Shanghai Pharmaceuticals Holding Co. Ltd. established in Hong Kong). Since June 2012, Mr. SHEN acts as a non-executive Director of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.

Ltd.